WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Now Available: The U.S. Dredge Report 2025 — download today for expert dredging market insights and data → Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

4.960 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10
Open 4.960
Bid (Size) 4.850 (700)
Ask (Size) 5.340 (200)
Prev. Close 4.960
Today's Range 4.950 - 4.960
52wk Range 4.250 - 7.250
Shares Outstanding 28,919,810
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
From Candel Therapeutics
Via GlobeNewswire

Performance

YTD
-8.8%
-8.8%
1 Month
-3.3%
-3.3%
3 Month
-12.5%
-12.5%
6 Month
-21.3%
-21.3%
1 Year
+12.9%
+12.9%

More News

Read More
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer ↗
Via Stocktwits
News headline image
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Pricing of Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today ↗
Via Stocktwits
News headline image
Candel Therapeutics Announces Proposed $100 Million Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
From Candel Therapeutics
Via GlobeNewswire
News headline image
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards ↗
Via Benzinga
News headline image
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
From Candel Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Candel Therapeutics, Inc. - Common Stock publicly traded?
Yes, Candel Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Candel Therapeutics, Inc. - Common Stock trade on?
Candel Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Candel Therapeutics, Inc. - Common Stock?
The ticker symbol for Candel Therapeutics, Inc. - Common Stock is CADL on the Nasdaq Stock Market
What is the current price of Candel Therapeutics, Inc. - Common Stock?
The current price of Candel Therapeutics, Inc. - Common Stock is 4.960
When was Candel Therapeutics, Inc. - Common Stock last traded?
The last trade of Candel Therapeutics, Inc. - Common Stock was at 04/08/26 04:00 PM ET
What is the market capitalization of Candel Therapeutics, Inc. - Common Stock?
The market capitalization of Candel Therapeutics, Inc. - Common Stock is 143.44M
How many shares of Candel Therapeutics, Inc. - Common Stock are outstanding?
Candel Therapeutics, Inc. - Common Stock has 143M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.